CCP
FLGT icon

Corient Capital Partners’s Fulgent Genetics FLGT Stock Holding History

Corient Capital Partners’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,715
Closed -$575K – 752
2021
Q4 		$575K Buy
+5,715
New +$502K 0.04% 342

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Corient Capital Partners's FLGT Position: Q1 2022 in Review

Corient Capital Partners sold out of Fulgent Genetics (FLGT) in Q1 2022, closing a stake of 5,715 shares — an estimated $575K sold.

Corient Capital Partners first reported a position in FLGT in Q4 2021 and held it in 1 quarter. The position peaked at $575K in Q4 2021. 275 funds tracked by Wall St. Rank hold FLGT as of Q1 2022.

  • Corient Capital Partners reported no remaining Fulgent Genetics position as of Q1 2022 after selling out during the quarter.
  • Corient Capital Partners sold 5,715 Fulgent Genetics shares in Q1 2022, an estimated $575K.
  • Corient Capital Partners first reported a position in Fulgent Genetics in Q4 2021 and held it in 1 quarter.
  • Corient Capital Partners's Fulgent Genetics position peaked at $575K in Q4 2021.
  • 275 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2022.

Based on Corient Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.